<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04941703</url>
  </required_header>
  <id_info>
    <org_study_id>210598</org_study_id>
    <nct_id>NCT04941703</nct_id>
  </id_info>
  <brief_title>&quot;CHANGE COVID-19 Severity&quot;</brief_title>
  <acronym>CHANGE</acronym>
  <official_title>Investigation of Choice Alteration of the Gut Metagenome on COVID-19 Severity</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are conducting an investigator-initiated, single center, blinded, placebo-controlled,&#xD;
      randomized clinical trial evaluating magnesium citrate combined with a probiotic for the&#xD;
      treatment of adults hospitalized with COVID-19.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We are conducting an investigator-initiated, single center, blinded, placebo-controlled,&#xD;
      randomized clinical trial evaluating magnesium citrate combined with a probiotic for the&#xD;
      treatment of adults hospitalized with COVID-19. Patients, treating clinicians, and study&#xD;
      personnel will all be blinded to study group assignment.&#xD;
&#xD;
      This research study is being done to determine if taking oral magnesium citrate and a&#xD;
      probiotic will improve the outcome of adults hospitalized with COVID-19. In this study, half&#xD;
      of the participants will receive magnesium citrate plus a probiotic and half will receive a&#xD;
      placebo randomized 1:1. You will be placed in one of these 2 groups randomly, like the flip&#xD;
      of a coin. The investigational arm will receive one 10 oz. bottle of magnesium citrate to&#xD;
      drink once and 2 oral probiotic capsules to be taken twice a day for 6 days. We will also&#xD;
      collect a blood sample on Day 1 and Day 7 for CD4+ and CD8+ evaluation and will be collecting&#xD;
      data on each participants COVID-19 infection progression during hospitalization.&#xD;
&#xD;
      Assessments for this study will be done on day 7 and day 29 if the participant is still&#xD;
      hospitalized at those time points. If they have been discharged from the hospital before&#xD;
      these assessments, we will do these by phone. Each participant will also be contacted at 3&#xD;
      months to assess how they are doing. There will be no compensation for taking part in this&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">June 25, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">June 25, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Blinded, single-center, placebo-controlled randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in COVID Ordinal Outcome Scale</measure>
    <time_frame>Baseline through Day 7 after completion of therapy</time_frame>
    <description>Patient State&#xD;
Descriptor Score&#xD;
Uninfected&#xD;
Uninfected, no viral RNA detected&#xD;
0&#xD;
Ambulatory Mild Disease Asymptomatic, viral RNA detected&#xD;
Symptomatic, independent&#xD;
Symptomatic, assistance needed&#xD;
1&#xD;
2&#xD;
3 Hospitalized Moderate Disease Hospitalized, no oxygen needed&#xD;
Hospitalized, oxygen by mask or nasal prongs 4&#xD;
5 Hospitalized Severe Disease Hospitalized, oxygen by NIV or high flow&#xD;
Intubation and mechanical ventilation, pO2/FiO2 ≥150 or SpO2/FiO2 ≥200&#xD;
Mechanical ventilation, pO2/FiO2 &lt;150 (SpO2/FiO2 &lt;200) or vasopressors&#xD;
Mechanical ventilation, pO2/FiO2 &lt;150 and vasopressors, dialysis or ECMO 6&#xD;
7&#xD;
8&#xD;
9 Dead Dead 10</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>COVID-19 Infection</condition>
  <arm_group>
    <arm_group_label>Magnesium Citrate plus a Probiotic Arm:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants assigned to the magnesium citrate plus a probiotic arm will receive 1 bottle of magnesium citrate 296 mL PO once to be taken within a 4-hour period, (about 10 oz.). Because magnesium citrate remains within the intestinal lumen, a second bottle can be provided if there is limited bowel movement. Patients will be asked to take 2 capsules of probiotics twice daily for six days or until discharge, whichever is earlier.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomized to the placebo arm will receive matching placebo 296 mL PO once to be taken within a 4-hour period, (about 10 oz.) and 2 cellulose capsules twice daily for six days or until discharge, whichever is earlier. The placebo will be flavored to match the taste of the interventional arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Magnesium Citrate plus probiotic</intervention_name>
    <description>296 ml magnesium citrate</description>
    <arm_group_label>Magnesium Citrate plus a Probiotic Arm:</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years&#xD;
&#xD;
          2. Currently hospitalized or in an emergency department with anticipated hospitalization.&#xD;
&#xD;
          3. Symptoms of acute respiratory infection, defined as one or more of the following:&#xD;
&#xD;
               1. Cough&#xD;
&#xD;
               2. Fever (&gt; 37.5° C / 99.5° F)&#xD;
&#xD;
               3. Shortness of breath (operationalized as any of the following: subjective&#xD;
                  shortness of breath reported by patient or surrogate; tachypnea with respiratory&#xD;
                  rate ≥22 /minute; hypoxemia, defined as SpO2 &lt;92% on room air, new receipt of&#xD;
                  supplemental oxygen to maintain SpO2 ≥92%, or increased supplemental oxygen to&#xD;
                  maintain SpO2 ≥92% for a patient on chronic oxygen therapy).&#xD;
&#xD;
               4. Sore throat&#xD;
&#xD;
               5. Anosmia&#xD;
&#xD;
          4. Laboratory-confirmed SARS (Severe acute respiratory syndrome-Coronavirus 2 (SARS&#xD;
             CoV-2) infection within 10 days prior to randomization&#xD;
&#xD;
          5. Ability to manage own stool care&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prisoner&#xD;
&#xD;
          2. Pregnancy&#xD;
&#xD;
          3. Breast feeding&#xD;
&#xD;
          4. Current infectious or noninfectious diarrheal illness&#xD;
&#xD;
          5. Unable to randomize within 21 days after onset of acute respiratory infection symptoms&#xD;
&#xD;
          6. Unable to randomize after hospital arrival&#xD;
&#xD;
          7. Colonic obstruction&#xD;
&#xD;
          8. Unresolved hypovolemia&#xD;
&#xD;
          9. CrCl &lt;30ml/min&#xD;
&#xD;
         10. Hypermagnesemia&#xD;
&#xD;
         11. Diagnosis of Long QT syndrome&#xD;
&#xD;
         12. Known allergy to magnesium citrate or probiotic&#xD;
&#xD;
         13. Unresolved electrolyte imbalance such as hypokalemia or hypocalcemia. The patient can&#xD;
             be enrolled if electrolytes are corrected and sustained.&#xD;
&#xD;
         14. Receipt of &gt;1 dose of magnesium citrate or any other colonic cleanser in the 7 days&#xD;
             prior to enrollment&#xD;
&#xD;
         15. Inability to receive enteral medications&#xD;
&#xD;
         16. Refusal or inability to be contacted on Day 15 for clinical outcome assessment if&#xD;
             discharged prior to Day 15&#xD;
&#xD;
         17. Concurrent medical illness that interferes with clinical assessment Previous&#xD;
             enrollment in this trial&#xD;
&#xD;
         18. The treating clinical team does not believe equipoise exists regarding the use of&#xD;
             magnesium citrate plus a probiotic for the treatment of this patient.&#xD;
&#xD;
         19. Participating in any other COVID-19 therapeutic trial&#xD;
&#xD;
         20. Allergic to soy.&#xD;
&#xD;
         21. Lactose intolerant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wonder Drake, MD</last_name>
    <phone>615-322-2035</phone>
    <email>wonder.drake@vumc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Kerrigan</last_name>
    <phone>615-498-2246</phone>
    <email>amy.kerrigan@vumc.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wonder Drake</last_name>
      <phone>615-322-2035</phone>
      <email>wonder.drake@vumc.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 24, 2021</study_first_submitted>
  <study_first_submitted_qc>June 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2021</study_first_posted>
  <last_update_submitted>June 25, 2021</last_update_submitted>
  <last_update_submitted_qc>June 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>Wonder Drake</investigator_full_name>
    <investigator_title>Wonder Drake, MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium citrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

